For Q2 2025, Y-mAbs reported total revenue of 19,525,000, gross profit of 16,863,000 (86% margin), and a net loss of 3,239,000 (EPS: -0.07). U.S. DANYELZA net product revenue was 14,300,000 and Ex-U.S. was 4,700,000; segment revenue remained concentrated in DANYELZA, with RIT generating no product revenue. The company recognized 500,000 in license revenue and ended the quarter with 62,293,000 in cash and cash equivalents. :contentReference[oaicite:0]{index=0}

Y-mAbs reported a net loss of $5.2 million for the first quarter of 2025, an improvement from the $6.6 million net loss in the same period last year. Total revenues increased 5% year-over-year to $20.9 million, driven by a significant increase in Ex-U.S. DANYELZA revenue, partially offset by a decrease in U.S. DANYELZA revenue.

Y-mAbs' Q4 2024 revenue increased 13% year-over-year to $26.5 million, supported by international DANYELZA sales and a $2 million licensing payment. However, net loss widened to $6.8 million due to increased operating expenses and reduced gross profit margin. The company continues to expand its radiopharmaceutical business while strengthening the DANYELZA franchise.

Y-mAbs reported total net revenues of $18.5 million for Q3 2024, a 10% decrease compared to Q3 2023. The company continues to focus on DANYELZA commercial business and SADA PRIT platform development.

Y-mAbs Therapeutics reported a 10% increase in total DANYELZA net product revenues for Q2 2024, reaching $22.8 million. The growth was primarily driven by increased international revenues, while U.S. revenues saw a slight decline. The company is advancing its clinical trials and expects to complete Part A of its GD2-SADA Phase 1 trial in Q4 2024. Management reiterates anticipated cash runway into 2027.

Y-mAbs reported its Q1 2024 financial results, highlighting the highest quarter of U.S. demand for DANYELZA® since its launch and progress in clinical development initiatives, particularly the SADA PRIT Technology platform. The company's financial guidance for the full year 2024 was reiterated, expecting to continue operations into 2027.

Y-mAbs reported a net loss of $1.0 million for Q4 2023, with DANYELZA net product revenues reaching $23.4 million, a 42% increase compared to the same period in 2022. The company's cash and cash equivalents were approximately $78.6 million as of December 31, 2023, expected to support operations into 2027.

Y-mAbs Therapeutics, Inc. reported a 59% increase in DANYELZA net product sales, reaching $20 million in Q3 2023 compared to the same period in 2022. The company's total revenues increased by 63% to $20.5 million. They also reported a net loss of $7.7 million, significantly lower than the $27.5 million loss in Q3 2022. With $86.6 million in cash and cash equivalents, Y-mAbs anticipates funding operations into 2027.

Y-mAbs reported DANYELZA net product revenues of $20.8 million for the quarter ended June 30, 2023, representing an increase of 112% over the comparable period of 2022. The company's cash and cash equivalents are expected to support operations into 2026.

Y-mAbs Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2023.

Y-mAbs reported a net revenue increase of 228% compared to Q4 2021, driven by DANYELZA sales and license revenue. The company also implemented a restructuring plan and anticipates a reduction in annual operating expenses for 2023.

Y-mAbs announced its financial results for the quarter ended September 30, 2022 but the specific details were not provided in the filing.

Y-mAbs reported net revenues of $10.8 million. The highlight of the second quarter was FDA acceptance of their BLA filing for omburtamab. They had approximately $133.7 million in cash and cash equivalents as of June 30, 2022, and they continue to expect full year 2022 cash burn of $78-83 million.

Y-mAbs had a successful first quarter with DANYELZA revenues of $10.5 million, a 94% increase year-over-year. The company anticipates full-year 2022 DANYELZA revenues in the range of $45-50 million and expects its cash and anticipated revenues to support operations into mid-2024.

Y-mAbs reported fourth-quarter net revenues of $9.6 million, consisting of product revenues from DANYELZA sales. The company ended the year with $181.6 million in cash and cash equivalents.

Y-mAbs reported net revenues of $9.0 million for the quarter ended September 30, 2021 related to sales of DANYELZA. The company ended the quarter with a cash balance of $215.7 million.

Y-mAbs reported net revenues of $11.0 million for the quarter ended June 30, 2021, consisting of $9.0 million of DANYELZA revenues and $2.0 million of licensing revenue. The company ended the quarter with a cash balance of $233.6 million.

Y-mAbs reported a net income of $33.4 million for the first quarter of 2021, driven by DANYELZA sales and the monetization of the Priority Review Voucher. The company's cash balance stands at $252.3 million, positioning it well to advance its pipeline.

Y-mAbs reported its 2020 financial results, which included a net loss, revenues from licensing agreements, and increased operating expenses. The company had $114.6 million in cash and cash equivalents as of December 31, 2020.

Y-mAbs reported a net loss of $32.8 million, or ($0.82) per basic and diluted share, for the three months ended September 30, 2020, compared to a net loss of $23.9 million for the three months ended September 30, 2019.

Y-mAbs reported a net loss of $40.4 million, or $1.01 per basic and diluted share, for the three months ended June 30, 2020, compared to a net loss of $18.0 million for the three months ended June 30, 2019. The company had approximately $158.1 million in cash and cash equivalents as of June 30, 2020.

Y-mAbs reported a net loss of $26.2 million for the first quarter of 2020, compared to a net loss of $15.9 million for the same period in 2019. The company's cash and cash equivalents decreased by $21.4 million during the quarter, primarily due to increased operational costs associated with BLA submissions and commercial infrastructure build-up.

Y-mAbs reported a net loss for the year ended December 31, 2019 of $81.0 million, or $2.30 per basic and diluted share. The Company had approximately $207.1 million in cash and cash equivalents as of December 31, 2019.